Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Antiepileptic drugs (AEDs) are effective against seizures, but their use is often limited by adverse effects, among them psychiatric and behavioral ones including aggressive behavior (AB). Knowledge of the incidence, risk factors, and the underlying mechanisms of AB induced by AEDs may help to facilitate management and reduce the risk of such side effects. The exact incidence of AB as an adverse effect of AEDs is difficult to estimate, but frequencies up to 16% have been reported. Primarily, levetiracetam (LEV), perampanel (PER), and topiramate (TPM), which have diverse mechanisms of action, have been associated with AB. Currently, there is no evidence for a specific pharmacological mechanism solely explaining the increased incidence of AB with LEV, PER, and TPM. Serotonin (5-HT) and GABA, and particularly glutamate (via the AMPA receptor), seem to play key roles. Other mechanisms involve hormones, epigenetics, and “alternative psychosis” and related phenomena. Increased individual susceptibility due to an underlying neurological and/or a mental health disorder may further explain why people with epilepsy are at an increased risk of AB when using AEDs. Remarkably, AB may occur with a delay of weeks or months after start of treatment. Information to patients, relatives, and caregivers, as well as sufficient clinical follow-up, is crucial, and there is a need for further research to understand the complex relationship between AED mechanisms of action and the induction/worsening of AB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 8×
“Several studies suggest that LEV modulates neuronal cell function via additional pharmacological mechanisms including modulation of serotonergic and α2-adrenergic signaling paths as well as μ-opioid receptors [93].”
BackgroundInfluentialEstimation of the burden of active and life-time epilepsy: a meta-analytic approach
Ngugi, A. K., Bottomley, C., Kleinschmidt, I., Sander, J. W., & Newton, C. R. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02481.x · Cited by 1,447 · cited 1×
“7% in developed countries, epilepsy is the fourth most common neurologic disease after migraine, Alzheimer’s disease, and stroke [1, 2].”
BackgroundHow common are the "common" neurologic disorders?
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., & Zalutsky, R. (2007) · Neurology · doi:10.1212/01.wnl.0000252807.38124.a3 · Cited by 1,365 · cited 1×
“7% in developed countries, epilepsy is the fourth most common neurologic disease after migraine, Alzheimer’s disease, and stroke [1, 2].”
BackgroundPerampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial
French, J. A., Krauss, G. L., Wechsler, R. T., Wang, X.-F., DiVentura, B., Brandt, C., Trinka, E., O'Brien, T. J., Laurenza, A., Patten, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001930 · Cited by 329 · cited 1×
“2015 [76] RCT, t = 32–54 weeks n = 162 patients (man age: 28.”
Copy number variants are frequent in genetic generalized epilepsy with intellectual disability
Mullen, S. A., Carvill, G. L., Bellows, S., Bayly, M. A., Berkovic, S. F., Dibbens, L. M., Scheffer, I. E., & Mefford, H. C. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a95829 · Cited by 188 · cited 2×
“The epilepsy is frequently of generalized type [121].”
Background
Cited by
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“Moreover, Wolking et al. investigated the genetic risk of rare variants for drug response to three AEDs (including LEV treatment for at least 1 year) through an analysis of the sequencing, genotyping, variant selection, and annotation of an epileptic cohort derived from the EpiPGX Consortium, to identify genetic bioma…”
BackgroundInfluentialXiaoying, G., Guo, M., Jie, L., Yanmei, Z., Ying, C., Shengjie, S., Haiyan, G., Feixiang, S., Sihua, Q., & Jiahang, S. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15894 · Cited by 54
Fukuyama, K., & Okada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094473 · Cited by 22
Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13
“The mechanism that can underlie these effects might be related to the levetiracetam impact on the AMPA receptor [93].”
Background
Metadata
- Authors
- Hansen, C. C., Ljung, H., Brodtkorb, E., & Reimers, A.
- Venue
- Behavioural Neurology
- Publisher
- Wiley
- Published
- 2018-11-15
- Volume
- 2018
- Pages
- 1-18
- ISSN
- 0953-4180 (ISSN-L)
- 1875-8584
- OpenAlex
- W2900895191
- Cited by
- 124
- References
- 5
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel. https://app.cochat.ai/papers/10.1155/2018/2064027
- The paper
- Hansen, C. C., Ljung, H., Brodtkorb, E., & Reimers, A. (2018). Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel. Behavioural Neurology. https://doi.org/10.1155/2018/2064027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.